Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data

@article{Nakasa1998PredictionOD,
  title={Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data},
  author={Hiromitsu Nakasa and H. Nakamura and S Ono and M Tsutsui and Masahiro Kiuchi and Shigeru Ohmori and Mitsukazu Kitada},
  journal={European Journal of Clinical Pharmacology},
  year={1998},
  volume={54},
  pages={177-183}
}
Objective: The purposes of this study were to identify the P450 enzyme (CYP) responsible for zonisamide metabolism in humans by using expressed human CYPs and to predict drug interaction of zonisamide in vivo from in vitro data. Methods: Ten expressed human CYPs and human liver microsomes were used in the experiments for the identification of enzymes responsible for zonisamide metabolism and for the prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data… Expand
View on Springer
ncbi.nlm.nih.gov
46 Citations
Highly Influential Citations
1
Background Citations
12
Methods Citations
2
Results Citations
1

46 Citations

Citation Type

Citation Type

Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.
TLDR
It is demonstrated that the use of rhCYPs with SIMCYP provides a robust in vitro system for predicting the likelihood and magnitude of changes in clinical exposure of compounds as a consequence of CYP3A4 inhibition by a concomitantly administered drug. Expand
Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients
Carbamazepine is metabolized by CYP3A4 and several other cytochrome P450 enzymes. The potential effects of zonisamide on carbamazepine pharmacokinetics (PK) have not been well characterized, with… Expand
Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy
TLDR
The state of research on the effects of mutations of drug-metabolizing enzymes on the pharmacokinetics and pharmacodynamics of AED therapies is summarized and future directions for the dose-adjustment of A ED are discussed. Expand
Identification of cytochrome P-450 isoform(s) responsible for the metabolism of pimobendan in human liver microsomes.
TLDR
It is concluded that CYP1A2 is one of the major enzymes responsible for the O-demethylation of pimobendan and CYP3A may make a minor contribution at clinically relevant concentrations of the drug. Expand
A Mechanistic Approach to Antiepileptic Drug Interactions
  • G. Anderson
  • Chemistry, Medicine
  • The Annals of pharmacotherapy
  • 1998
TLDR
By understanding the mechanisms of drug interactions, the pharmacist can play a key role in patient care by anticipating and preventing AED drug interactions. Expand
Effects of the Antifungal Agents on Oxidative Drug Metabolism
TLDR
The interactions of ketoconazole with cyclosporin and tacrolimus have been applied for therapeutic purposes to allow a lower dosage and cost of the immunosuppressant and a reduced risk of fungal infections. Expand
Population Estimation Regarding the Effects of Cytochrome P450 2C19 and 3A5 Polymorphisms on Zonisamide Clearance
TLDR
It is demonstrated that the CYP2C19 genotype affects the ZNS metabolism in Japanese epileptic subjects and the clinical relevance of these changes remains to be explored in future studies. Expand
Quantitative Drug Interactions Prediction System (Q-DIPS)
TLDR
A computerised application, the quantitative drug interactions prediction system (Q-DIPS), to make both qualitative deductions and quantitative predictions on the basis of a database containing updated information on CYP substrates, inhibitors and inducers, as well as pharmacokinetic parameters is developed. Expand
Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs
TLDR
It is suggested that micafungin and amphotericin B would be unlikely to cause drug‐drug interactions by inhibition of CYP3A4 and MDR1 and the physicochemical mechanisms involved and impact on clinical treatment should be studied further. Expand
Effects of CYP2C19 and P450 Oxidoreductase Polymorphisms on the Population Pharmacokinetics of Clobazam and N-Desmethylclobazam in Japanese Patients With Epilepsy
TLDR
The results suggest that determining the CYP2C19 and/or POR genotypes is helpful for obtaining appropriate serum CLB and N-CLB concentrations and preventing an overdose when starting CLB therapy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 49 REFERENCES
Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions
TLDR
A database containing information about the clearance routes for over 300 drugs from multiple therapeutic classes, including analgesics, anti-infectives, psychotropics, anticonvulsants, cancer chemotherapeutics, gastrointestinal agents, cardiovascular agents and others, was constructed to assist in the semiquantitative prediction of the magnitude of potential interactions with drugs under development. Expand
Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation.
TLDR
The findings indicate that CYP3A4 is the principal catalyst of 10,11-epoxide formation in human liver, consistent with the number of inhibitory drug interactions associated with its clinical use, interactions that result from a perturbation of CYP 3A4 catalytic activity. Expand
Pharmacokinetic Interactions Between Antiepileptic Drugs
TLDR
Antiepileptic drug interactions represent a common clinical problem which has been compounded by the introduction of many new compounds in recent years, and some need only careful clinical monitoring, but others require prompt dosage adjustment. Expand
Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide.
TLDR
The metabolism of zonisamide to SMAP was almost completely inhibited by anti-P450 3A4 antibody but not by anti -P450 2C9 or anti- P450 2D6 antibodies, suggesting that the amount of P 450 3A enzyme may be a major factor influencing the level of metabolism ofZonisamideto SMAP in human liver microsomes. Expand
Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.
TLDR
The kinetics of 3-methoxymorphinan formation were studied in microsomal enzyme systems and a significant correlation was observed between dextromethorphan N-demethylase activity and midazolam 1'- and 4-hydroxylase activity. Expand
Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide.
TLDR
Results indicate that cytochrome(s) P-450 belonging to P- 450 3A subfamily may be predominantly responsible for the reductive metabolism of zonisamide in rat liver microsomes. Expand
Metabolism of the anticonvulsant agent zonisamide in the rat.
  • D. Stiff, M. Zemaitis
  • Chemistry, Medicine
  • Drug metabolism and disposition: the biological fate of chemicals
  • 1990
TLDR
The metabolism of zonisamide primarily involves reductive and conjugative mechanisms, with oxidation of this compound being of minor metabolic significance. Expand
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.
TLDR
The results presented in this study provide useful information for the study of drug biotransformation in humans and for the basis of drug toxicities, carcinogenesis and teratogenesis. Expand
Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative.
TLDR
Metabolism of zonisamide in vitro by hepatic subcellular fractions and cultured gastrointestinal flora produced a single metabolite, 2-(sulphamoylacetyl)-phenol (2-SMAP), by reductive cleavage of the 1,2-benzisoxazole ring. Expand
Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative
TLDR
The metabolism of zonisamide in vitro was characterized through aerobic and anaerobic incubations with rat liver subcellular fractions and cultured gastrointestinal microflora and produced a single metabolite, 2-(sulphamoylacetyl)-phenol (2-SMAP), by reductive cleavage of the 1,2-benzisoxazole ring. Expand
...
1
2
3
4
5
...